Our mission is to accelerate the development of vaccines and immunotherapies against major global diseases by decoding how the human immune system fights disease.
The Michelson Prizes for Human Immunology and Vaccine Research have been awarded to three investigators applying disruptive research concepts to significantly advance the development of future vaccines and immunotherapies. Winners were selected via a rigorous, global competition and will be awarded $150,000 to fund specific aspects of their research.
Telethon Kids Institute in Australia has joined the Human Vaccines Project as its first international scientific hub, bringing significant health and scientific expertise in the areas of vaccines as well as working in pediatric and indigenous populations. The institute’s capacity will enhance the Project’s efforts toward better vaccines and immunotherapies, as well as work towards a universal flu vaccine.
The Human Vaccines Project welcomes Moncef Slaoui, PhD, to its Board of Directors. Dr. Slaoui served as Chairman of Global R&D at GSK, and was instrumental in the development HPV, pneumococcal and rotavirus vaccines. In 2016, he was recognized as one of Fortune Magazine’s “50 Greatest World Leaders” for his work on under-researched diseases that are common in the developing world.
Influenza vaccines are in the news, and a new approach is urgently needed. Here is a summary of recent press coverage around our new initiative on a universal influenza vaccine: The Wall Street Journal, Time Magazine / Bloomberg, MSN, Aspen Institute, STAT, Genome Web and CNBC.
Flu represents one of our greatest health and societal risks. Wayne Koff (CEO, Human Vaccines Project), Peter Doherty (Nobel Laureate, University of Melbourne) and Margaret Hamburg (former FDA Commissioner) call for a new approach on flu vaccines driven by a greater understanding of how the human immune system fights disease.
The Michelson Prizes support young investigators applying innovative research concepts to significantly advance the development of future vaccines and therapies against major global diseases.
Seasonal and pandemic influenza represent one of our greatest public health threats. The Human Vaccines Project has launched the Universal Influenza Vaccine Initiative to address the underlying scientific barrier impeding the development of a broadly protective, universal influenza vaccine: the human immune response.
Scientists leading the clinical programs for the Human Vaccines Project reported high-level outcomes from two clinical studies aimed at decoding how the human immune system prevents and controls disease at the World Vaccine and Immunotherapy Congress in San Diego, California.
The Human Vaccines Project welcomes Dr. Marie-Paule Kieny to its Board of Directors. Dr. Kieny is currently Director of Research at INSERM leading collaborations with the international health research community, and has held various leadership positions at the World Health Organization (WHO).
Dr. Crowe Director of the Vanderbilt Vaccines Center and head of the Project’s Human Immunome Program talks about breakthrough efforts to harness the human immune system against disease.
The Human Vaccines Project and Vanderbilt University Medical Center today announced that they joined forces with Illumina, Inc., to decipher the human immunome, the genetic underpinnings of the immune system.
The Human Vaccines Project is pleased to welcome Jose-Maria Fernandez to the Board of Directors. Jose-Maria is currently managing partner at Altamar Credit, Altamar Capital Partners LLC, and has held numerous posts in the public sector including most recently serving as Director General of the Spanish Treasury.
The Pioneering mRNA Biotech Company has Joined the Human Vaccines Project to Advance Fundamental Understanding of the Immune System
The Human Vaccines Project and Boehringer Ingelheim Partner To Accelerate the Development of Cancer Vaccines and Immunotherapies